The combination of anti-PD-L1 agent atezolizumab with bevacizumab has been evaluated in a single-arm, open-label, nonrandomized clinical study in patients with rare cancers, which included 40 patients with advanced, progressive G1/G2 NETs (50% pancreatic, 50% extra-pancreatic NETs), with the ORR as the primary endpoint of the study [61]. This evidence concerns the gene CD274 and cancer.